Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 202 participants.

Also called NCT03948867

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03948867
Other papers using this trial's data
  • Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial The Lancet. Haematology, 2023-04 DOI, PubMed 36870358, PMC10132280 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Tanzania (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03948867. Non-randomized; no masking; primary purpose treatment. Start 2019-04-24 (actual); primary completion 2022-09-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
Condition
Sickle Cell Anemia in Children
Intervention (Drug)
Hydroxyurea
Intervention (Diagnostic test)
Elevated Arm TCD Examination
Intervention (Diagnostic test)
Normal Arm TCD Examination
Lead sponsor
Children's Hospital Medical Center, Cincinnati (class: other)
Collaborator
Bugando Medical Centre (class: not stated)
Collaborator
The American Society of Hematology (class: not stated)

Record details

Record id
cardio:ct-nct03948867
Content hash
fcce1fbcf3741d2f629174fa3aceff5c293912f093c84f9b954da5238b389be4